Volume 20, Number 9—September 2014
CME ACTIVITY - Synopsis
Confirmed Bacillus anthracis Infection among Persons Who Inject Drugs, Scotland, 2009–2010
Table 3
Initial administration of antibacterial drugs to persons who inject drugs and had Bacillus anthracis Infection, Scotland, UK, 2009–2010*
7 | + | + | + | – | – | – | – | – | – | – | – | – |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | + | – | + | + | – | – | + | – | – | – | – | – |
9 | + | + | – | – | + | + | + | + | + | + | – | – |
10 | + | + | – | – | + | + | – | – | – | – | – | – |
11 |
– |
– |
– |
– |
– |
– |
– |
– |
– |
– |
– |
+ |
Total, n = 27 | 21 (78) | 18 (67) | 16 (59) | 16 (59) | 14 (52) | 5 (19) | 3 (11) | 3 (11) | 2 (7) | 1 (4) | 1 (4) | 1 (4) |
*CLI, clindamycin; CIP, ciprofloxacin; BPC, benzylpenicillin (penicillin G); FLUX, flucloxacillin; MTZ, metronidazole; CRO, ceftriaxone; GEN, gentamicin; VAN, vancomycin; MEM, meropenem; TZP, piperacillin/tazobactam; AMC, amoxicillin/clavulanic acid; AMX, amoxicillin; +, antibacterial drug administered; –, antibacterial drug not administered.
†Patients for whom data were available are numbered in the order in which they sought care during the outbreak.
‡No. (%) patients receiving an antibacterial drug.
1These authors contributed equally to this article.